SG11202009344VA - Pharmaceutical combination products comprising a histone deacetylase (hdac) inhibitor and a tlr7 agonist and/or tlr8 agonist for the treatment of cancer - Google Patents
Pharmaceutical combination products comprising a histone deacetylase (hdac) inhibitor and a tlr7 agonist and/or tlr8 agonist for the treatment of cancerInfo
- Publication number
- SG11202009344VA SG11202009344VA SG11202009344VA SG11202009344VA SG11202009344VA SG 11202009344V A SG11202009344V A SG 11202009344VA SG 11202009344V A SG11202009344V A SG 11202009344VA SG 11202009344V A SG11202009344V A SG 11202009344VA SG 11202009344V A SG11202009344V A SG 11202009344VA
- Authority
- SG
- Singapore
- Prior art keywords
- agonist
- hdac
- cancer
- inhibitor
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18167403 | 2018-04-14 | ||
| PCT/EP2019/059651 WO2019197682A1 (en) | 2018-04-14 | 2019-04-15 | Pharmaceutical combination products comprising a histone deacetylase (hdac) inhibitor and a tlr7 agonist and/or tlr8 agonist for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009344VA true SG11202009344VA (en) | 2020-10-29 |
Family
ID=62002053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009344VA SG11202009344VA (en) | 2018-04-14 | 2019-04-15 | Pharmaceutical combination products comprising a histone deacetylase (hdac) inhibitor and a tlr7 agonist and/or tlr8 agonist for the treatment of cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210145799A1 (en) |
| EP (1) | EP3781557A1 (en) |
| JP (1) | JP2021521207A (en) |
| KR (1) | KR20200143440A (en) |
| CN (1) | CN112105611A (en) |
| AU (1) | AU2019250696A1 (en) |
| CA (1) | CA3096765A1 (en) |
| IL (1) | IL277582A (en) |
| MX (1) | MX2020010820A (en) |
| SG (1) | SG11202009344VA (en) |
| TW (1) | TW202012395A (en) |
| WO (1) | WO2019197682A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3821890A1 (en) * | 2019-11-18 | 2021-05-19 | Strumberg, Dirk | Pharmaceutical compositions comprising an inhibitor of a histon-deacetylase (hdaci) and an agonist of toll-like-receptor 7 and/or 8 (tlr7 and/or tlr8) and their use in the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | Methods and compositions related to irm compounds and toll-like receptor 8 |
| EP1599726A4 (en) | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | Selective modulation of tlr-mediated biological activity |
| JP2007524615A (en) | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | Low molecular weight Toll-like receptor (TLR) antagonist |
| MX2007010561A (en) * | 2005-03-15 | 2008-02-22 | Nycomed Gmbh | N-sulphonylpyrroles and their use as histone deacetylase inhibitors. |
| US7498409B2 (en) | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
| AU2006232773B2 (en) * | 2005-04-07 | 2012-04-12 | 4Sc Ag | Sulfonylpyrroles as histone deacetylase inhibitors |
| EP2100882A1 (en) * | 2008-03-12 | 2009-09-16 | 4Sc Ag | (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts |
| ES2436540T3 (en) | 2008-03-24 | 2014-01-02 | 4Sc Discovery Gmbh | New substituted imidazoquinolines |
| SG11201808913WA (en) | 2016-04-15 | 2018-11-29 | Dynavax Tech Corp | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer |
-
2019
- 2019-04-12 TW TW108112818A patent/TW202012395A/en unknown
- 2019-04-15 AU AU2019250696A patent/AU2019250696A1/en not_active Abandoned
- 2019-04-15 CN CN201980025588.7A patent/CN112105611A/en active Pending
- 2019-04-15 WO PCT/EP2019/059651 patent/WO2019197682A1/en unknown
- 2019-04-15 EP EP19716919.6A patent/EP3781557A1/en not_active Withdrawn
- 2019-04-15 SG SG11202009344VA patent/SG11202009344VA/en unknown
- 2019-04-15 JP JP2020556233A patent/JP2021521207A/en active Pending
- 2019-04-15 US US17/047,529 patent/US20210145799A1/en active Pending
- 2019-04-15 KR KR1020207032518A patent/KR20200143440A/en unknown
- 2019-04-15 MX MX2020010820A patent/MX2020010820A/en unknown
- 2019-04-15 CA CA3096765A patent/CA3096765A1/en not_active Abandoned
-
2020
- 2020-09-24 IL IL277582A patent/IL277582A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL277582A (en) | 2020-11-30 |
| EP3781557A1 (en) | 2021-02-24 |
| CN112105611A (en) | 2020-12-18 |
| JP2021521207A (en) | 2021-08-26 |
| WO2019197682A1 (en) | 2019-10-17 |
| CA3096765A1 (en) | 2019-10-17 |
| AU2019250696A1 (en) | 2020-10-15 |
| KR20200143440A (en) | 2020-12-23 |
| US20210145799A1 (en) | 2021-05-20 |
| MX2020010820A (en) | 2021-01-15 |
| TW202012395A (en) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202101307B (en) | Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof | |
| EP3624804A4 (en) | Histone deacetylases (hdacs) inhibitors | |
| MX2019008302A (en) | Bicyclic inhibitors of histone deacetylase. | |
| EP3565549A4 (en) | Selective histone deacetylase inhibitors for the treatment of human disease | |
| EP3737376A4 (en) | Selective histone deacetylase inhibitors for the treatment of human disease | |
| EP3889138A4 (en) | Histone acetylase p300 inhibitor and use thereof | |
| IL279940A (en) | Inhibitors of histone deacetylase | |
| EP3532054A4 (en) | Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof | |
| IL279920A (en) | Bicyclic inhibitors of histone deacetylase | |
| EP3535275A4 (en) | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a bcl-2 inhibitor and methods of use thereof | |
| MX2020001484A (en) | Bicyclic inhibitors of histone deacetylase. | |
| EP3883572A4 (en) | Pharmaceutical composition comprising histone deacetylase 6 inhibitors | |
| GB201803361D0 (en) | Histone deacetylase inhibitors | |
| EP3532065A4 (en) | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | |
| IL277582A (en) | Pharmaceutical combination products comprising a histone deacetylase (hdac) inhibitor and a tlr7 agonist and/or tlr8 agonist for the treatment of cancer | |
| EP3544600A4 (en) | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof | |
| EP3458444A4 (en) | Histone deacetylase 6 inhibitors and use thereof | |
| ZA201902340B (en) | Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer | |
| EP3876928A4 (en) | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection | |
| EP3829559A4 (en) | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection | |
| EP3600295A4 (en) | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | |
| EP3863641A4 (en) | Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate | |
| GB202009784D0 (en) | Histone deacetylase inhibitors | |
| GB201912813D0 (en) | Histone deacetylase inhibitors | |
| GB201907955D0 (en) | Histone deacetylase inhibitors |